PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--Today PerkinElmer introduces the DA 7350 instrument and software providing continuous quality control testing for food manufacturing processes.

PerkinElmer Launches DA 7350™ Instrument and Cloud-Based Software for Quality Control in Food Production

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc.

PerkinElmer to Present at BofA Global Healthcare Conference 2020

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

PerkinElmer (PKI) Down 0.2% Since Last Earnings Report: Can It Rebound?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider PerkinElmer (PKI).

Is PerkinElmer (PKI) a Great Growth Stock?

PerkinElmer to Present at Baird's 2020 Virtual Global Healthcare Conference

PerkinElmer's (PKI) Hand Sanitizer Analyzer can help lab professionals and scientists all over the world in their fight against COVID-19.

PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol

PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process 
of SARS-CoV-2 RT-PCR testing.

PerkinElmer Launches Workstations for Coronavirus Testing

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer announces its Hand Sanitizer Analyzer instrument tests for the presence of methanol with pass/fail results delivered in 30 seconds.

PerkinElmer Enhances Hand Sanitizer Analyzer to Detect Methanol in 30 Seconds or Less

PerkinElmer Launches Modular and Scalable explorer™ Workstations for High-throughput COVID-19 Detection

Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes PerkinElmer (PKI) a Strong Momentum Stock: Buy Now?

D.R. Horton

PulteGroup

QuidelOrtho Corp

West Pharmaceutical Services

A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.

Wall Street is Northbound Defying All Concerns: 5 Top Picks

PerkinElmer (PKI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can PerkinElmer (PKI) Run Higher on Rising Earnings Estimates?

PerkinElmer's (PKI) CEO Prahlad Singh on Q2 2020 Results - Earnings Call Transcript

PerkinElmer Announces Financial Results for the Second Quarter of 2020

Carrier Global

Fortive

Generac Holdings

Mettler-Toledo

Several important companies from technology sector will report results this week. A few of them, with a favorable Zacks Rank, are set to beat earnings estimates.

Buy 5 Technology  Stocks Set to Beat on Q2 Earnings This Week

PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for PerkinElmer (PKI) This Earnings Season?

Perkinelmer is trading within a buy range with earnings on tap for Jul. 28. The stock is approximately 4% above a 105.80 buy point from a first-stage flat base.

Perkinelmer At Top End Of Buy Range With Earnings Due

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer COVID-19 Data Dashboards to help the global scientific community accelerate the discovery of COVID-19 antivirals and vaccines.

PerkinElmer Launches Online, Open Access COVID-19 Data Dashboards to Accelerate Antiviral Therapeutics Research

PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.

PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis

Neurocrine Biosciences

Health Care Select Sector SPDR Fund

Health-care stocks keep hitting highs. Mark Newton of Newton Advisors and Danielle Shay of Simpler Trading share their favorite names.

Three health-care stocks to watch as sector hits records

PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer’s new AuroFlow® AQ Mycotoxin Platform tests for key, regulated mycotoxins in corn and wheat samples with speed, accuracy and convenience.

PerkinElmer Introduces AuroFlow® AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities

PerkinElmer (PKI) Is Up 3.6% in One Week: What You Should Know

Macquarie Infrastructure

Owens Corning

Portland General Electric

TransUnion

Sales growth is one of the most reliable metrics for picking profitable stocks amid a challenging operating backdrop.

5 Stocks With Robust Sales Growth Worth Betting on Right Now

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately 12% for the second quarter ended July 5, 2020. The strong revenue growth was driven by better-than-expected demand for PerkinElmer’s full-suite of solutions aimed at helping support customers’ COVID-19 testing needs across the globe. Demand for the Company’s RT-PCR

News for PerkinElmer Stock (PKI)